| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Boc-Hyp-OMe does not have a specific biological target. Its primary utility is as a chemical building block in organic synthesis, particularly in peptide chemistry and as a linker for ADCs and PROTACs. The compound serves as a protected hydroxyproline unit that can be incorporated into peptide chains while the Boc and methyl ester groups protect the amino and carboxyl groups, respectively, from unwanted reactions. Hydroxyproline is a major component of collagen, but in its protected form, the compound is not designed to interact with biological receptors or enzymes. Its value lies in its chemical properties as a synthetic intermediate.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [2].
Boc-Hyp-OMe does not exhibit pharmacological activity in vitro. As a protected amino acid derivative and linker, it is a synthetic intermediate rather than a bioactive compound. In vitro studies using this compound focus on its chemical reactivity, such as its use in peptide bond formation reactions or in the synthesis of ADCs and PROTACs, rather than assessments of pharmacological activity. The compound does not bind to receptors, inhibit enzymes, or produce cytotoxic effects in cell-based assays at concentrations typically used for synthesis. Its role in research is almost exclusively as a reagent for organic synthesis. |
| ln Vivo |
Boc-Hyp-OMe is not a pharmacologically active compound and therefore does not have defined in vivo activity as a drug. Its primary value is as a chemical building block and linker in synthetic chemistry. It is not intended for in vivo administration in any therapeutic context.
|
| Enzyme Assay |
In vitro assays for Boc-Hyp-OMe are primarily focused on its chemical properties and reactivity rather than biological activity. Standard protocols in peptide synthesis involve the use of this compound as a protected hydroxyproline building block. The compound is typically dissolved in polar aprotic solvents such as DMF or DCM and coupled to a growing peptide chain on a solid support using standard peptide coupling reagents such as HATU, HOBt, or DIC. The progress of the coupling reaction can be monitored by HPLC or TLC. The Boc group can be removed under acidic conditions (e.g., TFA), and the methyl ester can be removed under basic conditions, revealing the free amino and carboxyl groups for further functionalization or peptide chain elongation.
|
| Cell Assay |
In vitro cellular assays using Boc-Hyp-OMe are not performed, as the compound is a chemical reagent used in organic synthesis and linker chemistry rather than a bioactive molecule. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides, ADCs, and PROTACs.
|
| Animal Protocol |
In vivo animal studies with Boc-Hyp-OMe are not typically conducted, as the compound is a synthetic intermediate and linker rather than a pharmacologically active agent. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides and bioconjugates.
|
| ADME/Pharmacokinetics |
Boc-Hyp-OMe is not a drug candidate, and pharmacokinetic data are not available. As a protected amino acid derivative and linker, it is designed for chemical synthesis rather than systemic administration. Its use is confined to in vitro synthetic applications.
|
| Toxicity/Toxicokinetics |
The compound is generally considered to have low toxicity, consistent with its use as a chemical reagent. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. It is not classified as a highly toxic substance, but appropriate safety measures should be followed. Inhalation, ingestion, or skin contact should be avoided.
|
| References |
[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. |
| Additional Infomation |
Boc-Hyp-OMe (N-Boc-4-hydroxy-L-proline methyl ester, CAS 74844-91-0) is a protected amino acid derivative used as a building block in peptide synthesis and as a linker for ADCs and PROTACs. Its chemical formula is C₁₁H₁₉NO₅ and molecular weight is 245.28. The compound features a Boc-protected amino group and a methyl ester-protected carboxyl group. It is intended for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C11H19NO5
|
|---|---|
| Molecular Weight |
245.2723
|
| Exact Mass |
245.126
|
| CAS # |
74844-91-0
|
| Related CAS # |
rel-Boc-Hyp-OMe;1145663-09-7
|
| PubChem CID |
2734883
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
335.2±42.0 °C at 760 mmHg
|
| Melting Point |
92-96 °C(lit.)
|
| Flash Point |
156.6±27.9 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.501
|
| LogP |
-0.25
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
310
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O([H])[C@@]1([H])C([H])([H])N(C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[C@]([H])(C(=O)OC([H])([H])[H])C1([H])[H]
|
| InChi Key |
MZMNEDXVUJLQAF-SFYZADRCSA-N
|
| InChi Code |
InChI=1S/C11H19NO5/c1-11(2,3)17-10(15)12-6-7(13)5-8(12)9(14)16-4/h7-8,13H,5-6H2,1-4H3/t7-,8+/m1/s1
|
| Chemical Name |
1-O-tert-butyl 2-O-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0771 mL | 20.3857 mL | 40.7714 mL | |
| 5 mM | 0.8154 mL | 4.0771 mL | 8.1543 mL | |
| 10 mM | 0.4077 mL | 2.0386 mL | 4.0771 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
